Intelligence Hub
Market analytics and operational performance indicators
Current Report - September 25, 2025
Entered $75M agreement to acquire Mynaric AG plus $75M earnout.
Brief
Rocket Lab signed a Stock Purchase Agreement to buy all shares of German firm Mynaric AG from OC III and COF II for $75 million in cash or stock, subject to adjustments. Up to $75 million additional earnout tied to 2025-2027 revenue targets. Closing requires German Ministry of Foreign Affairs approval; potential unregistered stock issuance.
Detailed Brief
On September 25, 2025, Rocket Lab Corporation and its subsidiary entered a Purchase Agreement with sellers OC III LVS LIII LP and CO Finance II LVS I LLC to acquire 100% of Mynaric AG's ordinary shares. Consideration is $75M upfront (cash or RKLB common stock at buyer's option, valued via 20-day VWAP pre-closing), plus up to $75M post-closing earnout in cash/stock based on Mynaric's revenue performance in 2025, 2026, and 2027. Customary reps/warranties, covenants, and conditions apply, including regulatory approval from Germany's Ministry of Foreign Affairs. If stock issued, it's exempt under Section 4(a)(2)/Reg D; Rocket Lab to file resale registration within 30 days post-closing. This pending acquisition advances Rocket Lab's vertical integration in space systems, particularly laser optical communications essential for its satellite and launch businesses.
Key Telemetry
- • Acquisition of all Mynaric AG shares for $75M upfront (cash/stock).
- • Up to $75M earnout on 2025-2027 revenue targets.
- • Pending German Ministry of Foreign Affairs regulatory approval.
- • Stock consideration: unregistered under Reg D; resale registration planned.
- • Announced September 25, 2025; closing date TBD.
Impact Vector
Near-term, no immediate financial strain as upfront payment is manageable for Rocket Lab's cash position; potential mild dilution/share issuance avoided via cash option. Strategically significant for bolstering spacecomms capabilities via Mynaric's laser terminals, aligning with Electron/Neutron growth and constellation services. Positive for long-term revenue diversification; investors should watch regulatory timeline (could delay months) and post-close integration for synergies vs. execution risks.